Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA


Ad hoc announcement pursuant to Art. 53 LR

See original here:
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Related Posts